Remimazolam NeuroImaging

Part of paid clinical trials in Pittsburgh, Pennsylvania.

Sponsor
Keith M Vogt
Study ID
NCT07290205
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Anesthesia
  • Pain
  • Remimazolam

Eligibility Criteria

Sex
ALL
Age
18 Years - 59 Years
Healthy Volunteers
Accepted

Interventions

  • Remimazolam — DRUG
    Subjects in this group will receive an intravenous infusion of this drug, during a portion of the study.
  • Peripheral Nerve Stimulation — DEVICE
    Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired with a fixed number of the experimental cues, in a pattern that appears random to participants.

Study Details

This is a single-arm functional MRI study that will determine the effects of remimazolam on cognition and brain activity and connectivity at rest, during noxious stimulation, and during a memory encoding task

Key Dates

Start date
Mar 27, 2026
Status verified
Mar 2026
Primary completion
Dec 1, 2027
Completion
Dec 2, 2027

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Remimazolam+Pain
    Single-arm study. All subjects receive remimazolam and painful electric nerve stimulation, while being imaged with MRI, as described in the interventions.

Primary Outcome Measure

Explicit memory performance [ Time Frame: Day/Visit 2: 12-36 hours after day 1 session ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of PittsburghPittsburghPennsylvania15213
Keith M Vogt, MD, PhD
[email protected]
4126473147
Keith M. Vogt, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Pittsburgh, PA

By research site
University of Pittsburgh· Pittsburgh, PA

Related Studies